The coagulation barrier in xenotransplantation: Incompatibilities and strategies to overcome them

Current Opinion in Organ Transplantation

Volumn 13, Issue 2, 2008, Pages 178-183

  Cowan, Peter J ^a,b   D'Apice, Anthony J F ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Immunology Research Centre   (Australia)

Author keywords

Coagulation; Genetic modification; Platelets; Thrombosis; Xenograft

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1,3 GALACTOSYLTRANSFERASE; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; GAMMA INTERFERON; HEPARIN; PROTEIN C; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; BLOOD CLOTTING; DNA MODIFICATION; ENDOTHELIUM INJURY; GENE DELETION; GRAFT FAILURE; HEART GRAFT; HUMORAL IMMUNITY; KIDNEY GRAFT; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIMATE; REVIEW; SWINE; THROMBOCYTE ACTIVATION; THROMBOGENICITY; THROMBOSIS; XENOTRANSPLANTATION;

ANIMALS; BLOOD COAGULATION; GENETIC ENGINEERING; GRAFT REJECTION; ISLETS OF LANGERHANS TRANSPLANTATION; ORGAN TRANSPLANTATION; PLATELET ACTIVATION; THROMBOSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 40649097093     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f63c74     Document Type: Review

References (64)

1. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in nonimmunosuppressed baboons. Transplantation 2000; 69:2504-2515.
2. Menoret S, Plat M, Blancho G, et al. Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination. Transplantation 2004; 77:1468-1471.
3. Shimizu A, Yamada K, Yamamoto S, et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005; 16:2732-2745.
4. Shimizu A, Yamada K. Pathology of renal xenograft rejection in pig to nonhuman primate transplantation. Clin Transplant 2006; 20 (Suppl 15):46-52.
5. Chen G, Qian H, Starzl T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11:1295-1298.
6. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of a1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32-34.
7. Wu G, Pfeiffer S, Schroder C, et al. Coagulation cascade activation triggers early failure of pig hearts expressing human complement regulatory genes. Xenotransplantation 2007; 14:34-47.
8. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31.
9. Tseng YL, Kuwaki K, Dor FJ, et al. Alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation 2005; 80:1493-1500.
10. Houser SL, Kuwaki K, Knosalla C, et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11:416-425.
11. Shimizu A, Colvin RB. Pathological features of antibody-mediated rejection. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5:199-214.
12. Cooper DK, Dorling A, Pierson RN, et al. Alpha1,3- galactosyltransferase gene-knockout pigs for xenotransplantation: where do we go from here? Transplantation 2007; 84:1-7.
13. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27:1687-1693. This paper is an excellent review of tissue factor -mediated coagulation, containing new insights into the role of platelets and microparticles.
14. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208:327-339.
15. Maroney SA, Cunningham AC, Ferrel J, et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost 2006; 4:1114-1124.
16. Zhang J, Piro O, Lu L, Broze GJ. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108:623-627.
17. Taylor FB, Peer GT, Lockhart MS, et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685-1688.
18. Laszik Z, Mitro A, Taylor FB, et al. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 1997; 96:3633-3640.
19. Pike RN, Buckle AM, le Bonniec BF, Church FC. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J 2005; 272:4842-4851.
20. Cowan PJ. Coagulation and the xenograft endothelium. Xenotransplantation 2007; 14:7-12. This report summarizes what we believe is occurring to promote thrombosis at the endothelial surface of solid organ xenografts.
21. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63:749-758.
22. Kopp CW, Robson SC, Siegel JB, et al. Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells. Thromb Haemost 1998; 79:529-538.
23. Siegel JB, Grey ST, Lesnikoski B-A, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64:888-896.
24. Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66:244-251.
25. Rose AG, Cooper DKC. Venular thrombosis is the key event in the pathogenesis of antibody-mediated cardiac rejection. Xenotransplantation 2000; 7:31-41.
26. Shimizu A, Meehan SM, Kozlowski T, et al. Acute humoral xenograft rejection: destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts. Lab Invest 2000; 80:815-830.
27. Sis B, Famulski KS, Allanach KL, et al. IFN-gamma prevents early perforingranzyme-mediated destruction of kidney allografts by inducing donor class I products in the kidney. Am J Transplant 2007; 7:2301-2310. The authors raise the possibility that species-specific failure in protective interferon-γ signalling may contribute to microcirculatory collapse in xenografts.
28. Murray AG, Khodadoust MM, Pober JS, Bothwell ALM. Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1994; 1:57-63.
29. Sultan P, Murray AG, McNiff JM, et al. Pig but not human interferon-gamma initiates human cell-mediated rejection of pig tissue in vivo. Proc Natl Acad Sci USA 1997; 94:8767-8772.
30. Morrell CN, Sun H, Swaim AM, Baldwin WM. Platelets an inflammatory force in transplantation. Am J Transplant 2007; 7:2447-2454.
31. Kaneko M, Takafuta T, Cuyun-Lira O, et al. Evaluation of platelet function under high shear condition in the small-sized collagen bead column. J Lab Clin Med 2005; 146:64-75.
32. Pareti FI, Mazzucato M, Bottini E, Mannucci M. Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex. Br J Haematol 1992; 82:81-85.
33. Schulte am Esch J, Robson SC, Knoefel WT, et al. O-linked glycosylation and functional incompatibility of porcine von Willebrand factor for human platelet GPIb receptors. Xenotransplantation 2005; 12:30-37.
34. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25:33-39.
35. Yuen AH, Khalpey Z, Lavitrano M, et al. Differences in activities of the enzymes of nucleotide metabolism and its implications for cardiac xenotransplantation. Nucleosides Nucleotides Nucleic Acids 2006; 25:1221-1224.
36. Khalpey Z, Yuen AH, Lavitrano M, et al. Mammalian mismatches in nucleotide metabolism: implications for xenotransplantation. Mol Cell Biochem 2007; 304:109-117. This report is a sobering reminder that there may be many subtle physiological/ metabolic incompatibilities that could potentially cause problems when pig organs are transplanted into humans.
37. Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004; 172:5693-5701.
38. Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4:1958-1963.
39. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105:125-133.
40. Iino S, Abeyama K, Kawahara KI, et al. Thrombomodulin expression on Langerhans' islet: can endogenous 'anticoagulant on demand' overcome detrimental thrombotic complications in clinical islet transplantation? J Thromb Haemost 2004; 2:833-834.
41. Glaser CB, Morser J, Clarke JH, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 1992; 90:2565-2573.
42. Rood PP, Bottino R, Balamurugan AN, et al. Reduction of early graft loss after intraportal porcine islet transplantation in monkeys. Transplantation 2007; 83:202-210. This study highlights the difficulty of preventing IBMIR of islet xenografts, even with systemic anticoagulation.
43. Buhler L, Deng S, O'Neil J, et al. Adult porcine islet transplantation in baboons treated with conventional immunosuppression or a nonmyeloablative regimen and CD154 blockade. Xenotransplantation 2002; 9:3-13.
44. Hering BJ, Wijkstrom M, Graham ML, et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006; 12:301-303.
45. Cardona K, Korbutt GS, Milas Z, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12:304-306.
46. Cardona K, Milas Z, Strobert E, et al. Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am J Transplant 2007; 7:2260-2268. This work builds on two earlier seminal studies to demonstrate successful engraftment of adult pig islets in diabetic monkeys, treated with a costimulation blockade-based immunosuppressive regimen, in two out of five cases. This is further evidence that pig islet xenotransplantation is feasible in humans.
47. Cowan PJ, Aminian A, Barlow H, et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2:520-525.
48. Shiraishi M, Oshiro T, Taira K, et al. Improved hepatic microcirculation by human soluble urinary thrombomodulin in the xeno-perfused porcine liver. Transplantation 2001; 71:1046-1050.
49. Cozzi E, Simioni P, Boldrin M, et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005; 80:1501-1510.
50. Byrne GW, Schirmer JM, Fass DN, et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5:1011-1020.
51. Kuwaki K, Knosalla C, Dor FJ, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human antihuman CD154 mAb-based regimen. Am J Transplant 2004; 4:363-372.
52. Schirmer JM, Fass DN, Byrne GW, et al. Effective antiplatelet therapy does not prolong transgenic pig to baboon cardiac xenograft survival. Xenotransplantation 2004; 11:436-443.
53. Cabric S, Elgue G, Nilsson B, et al. Adenovirus-mediated expression of the anticoagulant hirudin in human islets: a tool to make the islets biocompatible to blood. Cell Transplant 2006; 15:759-767. Expression of hirudin on the islet surface reduced thrombogenicity but also compromised function. This demonstrates the potential benefits but also the potential pitfalls of gene transfer to isolated islets.
54. Johansson U, Elgue G, Nilsson B, Korsgren O. Composite islet-endothelial cell grafts: a novel approach to counteract innate immunity in islet transplantation. Am J Transplant 2005; 5:2632-2639.
55. Xie D, Smyth CA, Eckstein C, et al. Cytoprotection of PEG-modified adult porcine pancreatic islets for improved xenotransplantation. Biomaterials 2005; 26:403-412.
56. Miura S, Teramura Y, Iwata H. Encapsulation of islets with ultra-thin polyion complex membrane through poly(ethylene glycol)-phospholipids anchored to cell membrane. Biomaterials 2006; 27:5828-5835.
57. Stabler CL, Sun XL, Cui W, et al. Surface re-engineering of pancreatic islets with recombinant azido-thrombomodulin. Bioconjug Chem 2007; 18:1713-1715. A novel approach to protectively coating islets by incorporating a 'bioactive' layer.
58. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56:2008-2015. This report describes an extremely promising biochemical method for protecting islet allografts and potentially xenografts from IBMIR.
59. Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003; 76:1285-1288.
60. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA 2005; 102:12153-12158.
61. Dwyer KM, Robson SC, Nandurkar HH, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113:1440-1446.
62. Mu J, Qu D, Bartczak A, et al. Fgl2 deficiency causes neonatal death and cardiac dysfunction during embryonic and postnatal development in mice. Physiol Genomics 2007; 31:53-62.
63. Cowan PJ, Nottle MB, d'Apice AJF. Molecular recognition of xenoreactivity. Curr Opin Organ Transplant 2007; 12:30-36.
64. Dwyer KM, Mysore TB, Crikis S, et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82:428-432. This study by our group provides the first evidence that a transgenic approach may be a part of the solution to the problem of IBMIR.